Back to Search
Start Over
Transdermal Testosterone Attenuates Drug-Induced Lengthening of Both Early and Late Ventricular Repolarization in Older Men.
- Source :
-
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2021 Jun; Vol. 109 (6), pp. 1499-1504. Date of Electronic Publication: 2020 Nov 15. - Publication Year :
- 2021
-
Abstract
- We have previously reported that transdermal testosterone attenuates drug-induced QT interval lengthening in older men. However, it is unknown whether this is due to modulation of early ventricular repolarization, late repolarization, or both. In a secondary analysis of a prospective, randomized, double-blind, placebo-controlled three-way crossover study, we determined if transdermal testosterone and oral progesterone attenuate drug-induced lengthening of early and late ventricular repolarization, represented by the electrocardiographic measurements J-T <subscript>peak</subscript> c and T <subscript>peak</subscript> -T <subscript>end</subscript> , respectively, as well as T <subscript>peak</subscript> -T <subscript>end</subscript> /QT, a measure of transmural dispersion of repolarization. Male volunteers ≥ 65 years of age (n = 14) were randomized to receive transdermal testosterone 100 mg, oral progesterone 400 mg, or matching transdermal/oral placebo daily for 7 days. On the morning following the seventh day, subjects received intravenous ibutilide 0.003 mg/kg, after which electrocardiograms were performed serially. One subject was excluded due to difficulty in T-wave interpretation. Pre-ibutilide J-T <subscript>peak</subscript> c was lower during the testosterone phase than during progesterone and placebo (216 ± 23 vs. 227 ± 28 vs. 227 ± 21 ms, P = 0.002). Maximum post-ibutilide J-T <subscript>peak</subscript> c was also lower during the testosterone phase (233 ± 22 vs. 246 ± 29 vs. 248 ± 23 ms, P < 0.0001). Pre-ibutilide T <subscript>peak</subscript> -T <subscript>end</subscript> was not significantly different during the three phases, but maximum post-ibutilide T <subscript>peak</subscript> -T <subscript>end</subscript> was lower during the testosterone phase (80 ± 12 vs. 89 ± 18 vs. 86 ± 15 ms, P = 0.002). Maximum T <subscript>peak</subscript> -T <subscript>end</subscript> /QT was also lower during the testosterone phase (0.199 ± 0.023 vs. 0.216 ± 0.035 vs. 0.209 ± 0.031, P = 0.005). Progesterone exerted minimal effect on drug-induced lengthening of J-T <subscript>peak</subscript> c, and no effect on T <subscript>peak</subscript> -T <subscript>end</subscript> or T <subscript>peak</subscript> -T <subscript>end</subscript> /QT. Transdermal testosterone attenuates drug-induced lengthening of both early and late ventricular repolarization in older men.<br /> (© 2020 The Authors Clinical Pharmacology & Therapeutics © 2020 American Society for Clinical Pharmacology and Therapeutics.)
- Subjects :
- Administration, Cutaneous
Administration, Oral
Aged
Aged, 80 and over
Anti-Arrhythmia Agents administration & dosage
Anti-Arrhythmia Agents pharmacology
Cross-Over Studies
Double-Blind Method
Electrocardiography drug effects
Humans
Male
Progesterone administration & dosage
Progesterone therapeutic use
Prospective Studies
Sulfonamides administration & dosage
Sulfonamides pharmacology
Long QT Syndrome chemically induced
Long QT Syndrome drug therapy
Testosterone administration & dosage
Testosterone therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1532-6535
- Volume :
- 109
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Clinical pharmacology and therapeutics
- Publication Type :
- Academic Journal
- Accession number :
- 33020898
- Full Text :
- https://doi.org/10.1002/cpt.2072